Getting to the bottom of the cause in this 29-year-old woman illustrates the diagnostic co ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis. NICE has said Biogen's Tysabri can now be used by the NHS ...

Secondary progressive multiple sclerosis (SPMS) usually develops after years of relapsing-remitting multiple sclerosis (RRMS) and leads to steadily worsening symptoms and disability over time. SPMS ...

Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on natalizumab (originator and biosimilar) for treating highly active ...

DMTs slow the progression of multiple sclerosis and reduce relapse severity. Starting DMTs soon after diagnosis can help ...

The central role of Epstein-Barr virus in causing multiple sclerosis is examined to understand how it triggers the disease and presents new opportunities for treatment “Evidence is mounting that you ...

Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the ...

The National Medical Commission (NMC) has approved the addition of new postgraduate medical seats in MD and MS programmes for inclusion in MCC NEET PG 2025 counselling Round 3. According to an ...

The move follows a decision by the National Board of Examinations in Medical Sciences (NBEMS) to revise the qualifying percentiles for NEET PG 2025 in order to maximise seat utilisation After the ...